Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiwei Liu

Showing results (191-200 of 224) with videos related to

Pageof 23
Sort By:
ACS Nano|August 16, 2024
Low-Dose Mildronate-Derived Lipidoids for Efficient mRNA Vaccine Delivery with Minimal Inflammation Side EffectsJiwei Liu, Bing Xiao, Yongle Yang, et al.
Translational Oncology|April 14, 2019
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)Lu Si, Xiaoshi Zhang, Yongqian Shu, et al.
Theranostics|September 20, 2019
Membrane TLR9 Positive Neutrophil Mediated MPLA Protects Against Fatal Bacterial SepsisZhaogang Yang, Luowei Wang, Hongmei Yu, et al.
Journal of the American Academy of Dermatology|November 22, 2024
Nevus-associated acral melanoma has lower risk of recurrence and mortality than de novo acral melanoma: A multicenter, retrospective analysis of 482 patientsYiqun Zhang, Jin Wu, Xin Cai, et al.
Journal of the American Academy of Dermatology|May 30, 2026
Response to Zun-Jiang Zhao et al., "Comment on 'Nevus-associated acral melanoma has lower risk of recurrence and mortality than de novo acral melanoma'."Yiqun Zhang, Jin Wu, Xin Cai, et al.
Nature Communications|January 25, 2020
Impaired lipid biosynthesis hinders anti-tumor efficacy of intratumoral iNKT cellsSicheng Fu, Kaixin He, Chenxi Tian, et al.
Immunotherapy|July 19, 2023
Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in AsiaYing Cheng, James Chih-Hsin Yang, Isamu Okamoto, et al.
Cancer Letters|July 30, 2018
USP10 suppresses tumor progression by inhibiting mTOR activation in hepatocellular carcinomaChang Lu, Zhen Ning, Aman Wang, et al.
The Lancet. Respiratory Medicine|June 6, 2022
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 studyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 6, 2022
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG StudyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Pageof 23

Showing results (191-200 of 224) with videos related to

Sort By:
Pageof 23
ACS Nano|August 16, 2024
Low-Dose Mildronate-Derived Lipidoids for Efficient mRNA Vaccine Delivery with Minimal Inflammation Side EffectsJiwei Liu, Bing Xiao, Yongle Yang, et al.
Translational Oncology|April 14, 2019
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)Lu Si, Xiaoshi Zhang, Yongqian Shu, et al.
Theranostics|September 20, 2019
Membrane TLR9 Positive Neutrophil Mediated MPLA Protects Against Fatal Bacterial SepsisZhaogang Yang, Luowei Wang, Hongmei Yu, et al.
Journal of the American Academy of Dermatology|November 22, 2024
Nevus-associated acral melanoma has lower risk of recurrence and mortality than de novo acral melanoma: A multicenter, retrospective analysis of 482 patientsYiqun Zhang, Jin Wu, Xin Cai, et al.
Journal of the American Academy of Dermatology|May 30, 2026
Response to Zun-Jiang Zhao et al., "Comment on 'Nevus-associated acral melanoma has lower risk of recurrence and mortality than de novo acral melanoma'."Yiqun Zhang, Jin Wu, Xin Cai, et al.
Nature Communications|January 25, 2020
Impaired lipid biosynthesis hinders anti-tumor efficacy of intratumoral iNKT cellsSicheng Fu, Kaixin He, Chenxi Tian, et al.
Immunotherapy|July 19, 2023
Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in AsiaYing Cheng, James Chih-Hsin Yang, Isamu Okamoto, et al.
Cancer Letters|July 30, 2018
USP10 suppresses tumor progression by inhibiting mTOR activation in hepatocellular carcinomaChang Lu, Zhen Ning, Aman Wang, et al.
The Lancet. Respiratory Medicine|June 6, 2022
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 studyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 6, 2022
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG StudyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Pageof 23